KR102375097B1 - 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 - Google Patents

항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 Download PDF

Info

Publication number
KR102375097B1
KR102375097B1 KR1020210130307A KR20210130307A KR102375097B1 KR 102375097 B1 KR102375097 B1 KR 102375097B1 KR 1020210130307 A KR1020210130307 A KR 1020210130307A KR 20210130307 A KR20210130307 A KR 20210130307A KR 102375097 B1 KR102375097 B1 KR 102375097B1
Authority
KR
South Korea
Prior art keywords
compound
formula
klotho
expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020210130307A
Other languages
English (en)
Korean (ko)
Inventor
정동주
Original Assignee
주식회사 클로소사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 클로소사이언스 filed Critical 주식회사 클로소사이언스
Application granted granted Critical
Publication of KR102375097B1 publication Critical patent/KR102375097B1/ko
Priority to PCT/KR2022/004341 priority Critical patent/WO2022211420A1/ko
Priority to CN202280026649.3A priority patent/CN117136055A/zh
Priority to US18/553,414 priority patent/US20240358683A1/en
Priority to BR112023019984A priority patent/BR112023019984A2/pt
Priority to CA3213904A priority patent/CA3213904A1/en
Priority to EP22781539.6A priority patent/EP4316487A4/en
Priority to AU2022251900A priority patent/AU2022251900B2/en
Priority to JP2023561185A priority patent/JP7728031B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020210130307A 2021-04-01 2021-09-30 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 Active KR102375097B1 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2023561185A JP7728031B2 (ja) 2021-04-01 2022-03-28 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物を含む退行性神経疾患の予防または治療用組成物
BR112023019984A BR112023019984A2 (pt) 2021-04-01 2022-03-28 Composição para prevenir ou tratar doenças neurodegenerativas compreendendo compostos que induzem a expressão do gene antienvelhecimento klotho
CN202280026649.3A CN117136055A (zh) 2021-04-01 2022-03-28 包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗退行性神经疾病的组合物
US18/553,414 US20240358683A1 (en) 2021-04-01 2022-03-28 Composition for preventing or treating neurodegenerative disease comprising compound inducing expression of anti-aging gene klotho
PCT/KR2022/004341 WO2022211420A1 (ko) 2021-04-01 2022-03-28 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물
CA3213904A CA3213904A1 (en) 2021-04-01 2022-03-28 Composition for preventing or treating neurodegenerative disease comprising compounds that induces the expression of anti-aging gene klotho
EP22781539.6A EP4316487A4 (en) 2021-04-01 2022-03-28 Composition for the prevention or treatment of neurodegenerative diseases containing a compound for inducing the expression of the anti-aging gene Klotho
AU2022251900A AU2022251900B2 (en) 2021-04-01 2022-03-28 Composition for preventing or treating neurodegenerative disease comprising compound inducing expression of anti-aging gene klotho

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020210042958 2021-04-01
KR20210042958 2021-04-01

Publications (1)

Publication Number Publication Date
KR102375097B1 true KR102375097B1 (ko) 2022-03-17

Family

ID=80936324

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020210130307A Active KR102375097B1 (ko) 2021-04-01 2021-09-30 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Country Status (9)

Country Link
US (1) US20240358683A1 (https=)
EP (1) EP4316487A4 (https=)
JP (1) JP7728031B2 (https=)
KR (1) KR102375097B1 (https=)
CN (1) CN117136055A (https=)
AU (1) AU2022251900B2 (https=)
BR (1) BR112023019984A2 (https=)
CA (1) CA3213904A1 (https=)
WO (1) WO2022211420A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022211420A1 (ko) * 2021-04-01 2022-10-06 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7728030B2 (ja) * 2021-04-01 2025-08-22 クロトー サイエンシーズ カンパニー リミテッド 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物を含む慢性腎疾患の予防または治療用組成物
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070057779A (ko) 2004-07-16 2007-06-07 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 베타-아밀로이드 펩티드 생산을 저해함으로써알츠하이머병을 치료하는 화합물 및 이들의 제조
KR20110137868A (ko) * 2010-06-18 2011-12-26 이화여자대학교 산학협력단 Ｉｎｔｅｒｌｅｕｋｉｎ―６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR101446301B1 (ko) * 2013-04-11 2014-10-06 서울대학교산학협력단 Cxcr3/cxcl10 길항제 화합물, 이의 제조방법 및 이를 포함하는 골 전이의 예방 및 치료용 약학 조성물
KR20160069736A (ko) * 2014-12-09 2016-06-17 (주)아모레퍼시픽 메틸화된 카테킨을 유효성분으로 함유하는 Klotho 유전자 활성화용 조성물
KR20170024522A (ko) * 2015-08-24 2017-03-07 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
KR20190041897A (ko) * 2017-10-13 2019-04-23 이화여자대학교 산학협력단 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088770A (en) * 1971-05-04 1978-05-09 Eli Lilly And Company Substituted 2-anilinobenzoxazoles used as immunosuppressive agents
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
EP1910385B1 (en) * 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
WO2010039186A2 (en) * 2008-09-23 2010-04-08 Renovis, Inc. Compounds useful as faah modulators and uses thereof
WO2010129954A1 (en) * 2009-05-08 2010-11-11 Apogee Biotechnology Corporation Treatment of ischemia-reperfusion injury
US10647689B2 (en) 2015-04-28 2020-05-12 Sanford Burnham Prebys Medical Discovery Institute Apelin receptor agonists and methods of use thereof
KR102522955B1 (ko) 2018-09-26 2023-04-19 미쓰비시 덴키 빌딩 솔루션즈 가부시키가이샤 엘리베이터 시스템 및 휴대 단말
JP7412546B2 (ja) 2019-10-02 2024-01-12 克洛索科学公司 抗老化遺伝子ｋｌｏｔｈｏの発現を誘導する化合物およびその用途
KR102749973B1 (ko) 2020-04-21 2025-01-06 엘지마그나 이파워트레인 주식회사 전기모터 및 이를 구비한 전기차량
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070057779A (ko) 2004-07-16 2007-06-07 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 베타-아밀로이드 펩티드 생산을 저해함으로써알츠하이머병을 치료하는 화합물 및 이들의 제조
KR20110137868A (ko) * 2010-06-18 2011-12-26 이화여자대학교 산학협력단 Ｉｎｔｅｒｌｅｕｋｉｎ―６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR101446301B1 (ko) * 2013-04-11 2014-10-06 서울대학교산학협력단 Cxcr3/cxcl10 길항제 화합물, 이의 제조방법 및 이를 포함하는 골 전이의 예방 및 치료용 약학 조성물
KR20160069736A (ko) * 2014-12-09 2016-06-17 (주)아모레퍼시픽 메틸화된 카테킨을 유효성분으로 함유하는 Klotho 유전자 활성화용 조성물
KR20170024522A (ko) * 2015-08-24 2017-03-07 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
KR20190041897A (ko) * 2017-10-13 2019-04-23 이화여자대학교 산학협력단 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022211420A1 (ko) * 2021-04-01 2022-10-06 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
EP4316487A1 (en) 2024-02-07
CA3213904A1 (en) 2022-10-06
CN117136055A (zh) 2023-11-28
JP7728031B2 (ja) 2025-08-22
AU2022251900B2 (en) 2025-09-18
US20240358683A1 (en) 2024-10-31
EP4316487A4 (en) 2025-04-09
JP2024512818A (ja) 2024-03-19
AU2022251900A9 (en) 2023-11-09
AU2022251900A1 (en) 2023-10-26
WO2022211420A1 (ko) 2022-10-06
BR112023019984A2 (pt) 2024-04-02

Similar Documents

Publication Publication Date Title
KR102530597B1 (ko) 항노화 유전자 klotho의 발현을 유도하는 화합물 및 이의 용도
KR102375097B1 (ko) 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물
EP2064200B1 (en) Derivatives of 2-phenyl-3-hydroxyquinoline-4(1h)-one and methods of their preparation and utilization
CN114341103B (zh) 作为可用来治疗神经疾病的逆运体稳定剂的氨基胍腙
TW201538516A (zh) 異類葉升麻苷衍生物及其製造方法與用途
EP3818046B1 (en) Lactate enhancing compounds and uses thereof
KR102463786B1 (ko) 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물
EP4317140A1 (en) Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho
KR102530601B1 (ko) 항노화 유전자 klotho의 발현을 유도하는 신규 화합물
CN117157280A (zh) 包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗慢性肾脏疾病的组合物
KR102401818B1 (ko) 신규 3-(벤조일)-2-티옥소이미다졸리딘-4-온 유도체 화합물 및 이의 용도
KR102082041B1 (ko) 에피갈로카테킨 갈레이트 프로드러그, 이의 제조방법 및 이를 포함하는 미토콘드리아 생합성 촉진용 조성물
EP4353710A1 (en) Novel indole derivative, and use thereof for treating diseases related to advanced glycation end products
WO2023182735A1 (ko) 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 황반변성의 예방 또는 치료용 조성물
JP5561648B2 (ja) ロダシアニン誘導体及びリーシュマニア感染症治療用医薬組成物

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000